Patent eligibility reform

Summary#

This bill changes the federal patent eligibility rules in Title 35 of the U.S. Code. It says courts should not apply the previous “judicial exceptions” and sets a broader rule that most useful processes, machines, manufactures, or compositions of matter (and useful improvements) can be patented, subject to specific exclusions. The bill aims to make patent law clearer and to restore eligibility for inventions some courts have treated as ineligible.

• Main change: Eliminates judicial exceptions and states that eligibility is determined by the statute’s text, with five named exclusions (certain math formulas, mental processes, unmodified human genes, unmodified natural materials, and processes that are substantially economic/financial/business/social/cultural/artistic).
• Key rule: Eligibility must be decided by looking at the claimed invention as a whole and not by considering novelty, nonobviousness, or specification rules.
• Conditions: A claimed invention that cannot practically be performed without a machine or manufacture may still be eligible even if it involves math or business-type steps. Human genes or natural materials are not “unmodified” if they are purified, enriched, altered, or otherwise employed in a useful invention.
• Court process: Courts can rule on eligibility in infringement cases and may allow limited discovery focused only on eligibility.
• Safety valve: The bill does not change the doctrine of obviousness-type double patenting and says merely tacking on computer steps that are not necessary does not make a claim eligible.

What it means for you#

• Inventors and patent applicants

  • You could be more likely to get an eligibility decision that allows patents on software-related inventions, business-method-like processes that require a machine, and many types of practical inventions that some courts had treated as ineligible.
  • If your invention involves a gene or natural material, it may be patentable if the gene/material is purified, enriched, altered, or otherwise used in a useful invention.
  • Patent eligibility will be judged without discounting any claim element and without looking to novelty, obviousness, or specification requirements.

• Businesses and startups

  • Companies that rely on patents for software, diagnostics, biotech, or certain process innovations may find a clearer path to patents.
  • The scope of what counts as a patentable process may widen, especially for inventions that require a machine to be practical.

• Patent examiners and the U.S. Patent and Trademark Office (USPTO)

  • Examination practice would need to follow the statutory text: examiners must evaluate eligibility by the whole claim and not apply judicial exceptions or exclude claim elements because they are conventional.
  • The PTO may need new guidance and training to implement these changes.

• Courts and litigants

  • Courts would be limited to the statutory eligibility criteria and may not use previously developed judicial exceptions.
  • Parties can seek early court rulings on eligibility with limited discovery on that issue.

• Researchers, clinicians, and the public

  • Purely unmodified human genes and natural materials, as they exist in the body or in nature, would remain unpatentable. But altered or purified biological material can be considered modified and thus eligible.
  • This could affect who can obtain exclusive rights to certain biotech tests or products, depending on whether materials are altered.

Expenses#

No publicly available information.

• The bill text does not include a fiscal note or estimate of costs to the federal government, the USPTO, courts, or private parties.
• Potential cost areas (not quantified in the bill) include updated USPTO guidance and training, possible increased patent filings, and litigation over the scope and application of the new wording.

Proponents' View#

• The bill appears intended to restore the statutory reach of patent eligibility and reduce confusion from court-made exceptions.
• Supporters may argue that this approach would make eligibility clearer and more predictable by:
  • Directly defining what is excluded and removing judge-made doctrines.
  • Requiring courts and examiners to consider claims as a whole and not treat conventional or known elements as automatically disqualifying.
  • Allowing patents on practical inventions that depend on machines or on altered/used biological materials.

Opponents' View#

• One concern is that the bill’s broad eligibility rules may allow patents on inventions that rely mainly on routine or conventional elements, because courts would not be allowed to consider conventionality when deciding eligibility.
• The categories being excluded (for example, “substantially economic, financial, business, social, cultural, or artistic”) are vague; it is unclear where the line will fall between eligible and excluded processes.
• The phrase “cannot practically be performed without the use of a machine” is open to interpretation and could lead to disputes about whether adding a computer or device actually makes a process eligible.
• The change could increase patenting and litigation in fields such as software and biotechnology; whether this creates benefits or burdens is not quantified in the bill.
• It is unclear how this statutory rule will interact with existing PTO practice and prior court decisions not expressly overruled by Congress under this bill.